Skip to main content
logo
Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
3.825
-0.055 (-1.42%)
At close: Sep 8, 2026, 4:00 PM EDT
3.700
-0.180 (-4.64%)
Pre-market: Sep 9, 2026, 7:36 AM EDT

Galmed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
3.633.643.33.924.665.66
Research & Development
6.324.872.983.571327.22
Operating Expenses
9.968.516.287.4917.6532.88
Operating Income
-9.96-8.51-6.28-7.49-17.65-32.88
Interest Expense
-0.15-0.08-0.61---
Interest & Investment Income
1.030.910.50.380.30.56
Currency Exchange Gain (Loss)
-0.08-0.080.04-0.040.04-0.03
Other Non Operating Income (Expenses)
-0.02-0.02-0.020.25-0.02-0.04
EBT Excluding Unusual Items
-9.17-7.77-6.36-6.9-17.34-32.39
Gain (Loss) on Sale of Investments
-2.18-2.54-1.16-0.01-0.53-0.08
Pretax Income
-11.34-10.31-7.52-6.91-17.87-32.47
Net Income
-11.34-10.31-7.52-6.91-17.87-32.47
Net Income to Common
-11.34-10.31-7.52-6.91-17.87-32.47
Net Income Growth
------
Shares Outstanding (Basic)
110000
Shares Outstanding (Diluted)
110000
Shares Change
214.95%363.17%303.32%65.23%2.21%15.59%
EPS (Basic)
-14.11-19.13-64.61-239.59-1023.25-1900.66
EPS (Diluted)
-14.11-19.13-64.61-239.59-1023.25-1900.66
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-8.54-6.32-5.88-6.14-18.51-32.9
Free Cash Flow Per Share
-10.62-11.72-50.54-212.73-1059.85-1926.18
EBITDA
--8.43-6.2-7.46-17.62-32.84
D&A For EBITDA
-0.080.080.030.040.04
EBIT
-9.96-8.51-6.28-7.49-17.65-32.88
SEC Filings: 10-K · 10-Q